Monotherapy is a possibility of simplifying an antiretroviral therapy regimen

Aleksey Viktorovich Kravchenko; U A Kuimova; A V Kravchenko; U A Kuimova

doi:10.17816/EID40501

Epidemiology and Infectious Diseases ›› 2010, Vol. 15 ›› Issue (5) : 48 -50. DOI: 10.17816/EID40501

Articles

other

Monotherapy is a possibility of simplifying an antiretroviral therapy regimen

Author information +

History +

PDF

Abstract

The European AIDS Clinical Society guidelines (November 2009, Version 5) are the first to propose to use ritonavir-boosted protease inhibitors (PI) as monotherapy. These treatment regimens may be the modality of choice for HIV-infected patients if nucleoside reverse transcriptase inhibitors (NRTI) are not tolerated or the ART regimen should be simplified.The paper gives the results of the largest studies (MONET, OK04, OREY) dealing with switching from a standard ART regimen (2 NRTIs + PI) to PI monotherapy. The results of these studies provide strong evidence that ART regimen simplification to boosted PI monotherapy did not affect in the least therapeutic efficiency. After 48-96 weeks of monotherapy, treatment failure was recorded in 15-23% of patients; however, return to the previous therapeutic regime (addition of two former drugs from a NRTI group) allowed complete suppression of virus replication to be achieved again in 80% of cases. Development of PI resistance mutations in HIV was recorded only in single patients. PI monotherapy regimens were well tolerated, there were no adverse reactions associated with the use of NRTIs.

Keywords

HIV infection / antiretroviral therapy / HIV monotherapy with protease inhibitors

Cite this article

Download citation ▾

Aleksey Viktorovich Kravchenko, U A Kuimova, A V Kravchenko, U A Kuimova. Monotherapy is a possibility of simplifying an antiretroviral therapy regimen. Epidemiology and Infectious Diseases, 2010, 15(5): 48-50 DOI:10.17816/EID40501

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	ВИЧ-инфекция и СПИД / Под ред. В. В. Покровского. - 2-е изд. - М., 2010.

[2]	Arribas J. R., Delgado R., Arranz A. et al. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis // J. Acquir Immune Defic. Syndr. - 2009. - Vol. 51. - P. 147-152.

[3]	Bierman W. F. W., van Agtmael M. A., Nijhuis M. HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review // AIDS. - 2009. - Vol. 23. - P. 279-291.

[4]	European AIDS Clinical Society Issues New Guidelines for Treatment of HIV, Version 5, November, 2009 (http://www.europeanaidsclinicalsociety.org).

[5]	McKinnon J. E., Mellors J. W., Swindells S. Simplification strategies to reduce antiretroviral drug exposure: progress and prospects // Antiviral Ther. - 2009. - Vol. 14. - P. 1-12.

[6]

Pulildo F., Serrano O., Rivero A. et al. Atazanavir/ritonavir monotherapy for maintenance of virologic suppression: 48 week primary analysis of the 96 week multicenter, open-label, single-arm, pilot OREY study // 12th European AIDS Conference. Cologne, Germany. Nov. 11-13, 2009. - Cologne, 2009. - Abstr. PS4/6.

[7]	Ripamonti D, Arribas J., Pulildo F., Hill A. Non-inferior efficacy shown across different efficacy endpoints in the MONET trial of darunavir/ritonavir monotherapy // 12th European AIDS Conference. Cologne, Germany. Nov. 11-13, 2009. - Cologne, 2009. - Abstr. PS4/1.

[8]	Vogel M., Ahlenstiel G., Klausen G. et al. The effect of Nucleoside free HAART on the treatment of chronic HCV infection // 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town, South Africa, 19-22 July 2009. - Cape Town, 2009. - Poster WEPEB235.